4,203 results match your criteria: "Alloimmunization From Transfusions"
Fetal Diagn Ther
September 2024
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Introduction: To compare the blood volume transfused for fetal anemia in cases of placental chorioangioma versus red blood cell (RBC) alloimmunization in patients matched for gestational age (GA) and hydrops.
Methods: Study patients had intrauterine transfusions and were obtained from 3 sources: group (1) placental chorioangioma patients treated at our center (2016-2023); group (2) placental chorioangioma patients reported in the medical literature; and group (3) RBC alloimmunization patients treated for fetal anemia at our center (2016-2023) matched (2:1) to patients in groups 1 and 2 by GA at procedure and presence of hydrops. The expected volume (cc) of transfusion was calculated for all patients based on a formula commonly used for fetal anemia in cases of RBC alloimmunization that includes the GA at procedure, pre-transfusion hemoglobin, donor hemoglobin, and target hemoglobin.
Transfusion
October 2024
Blood Transfusion and Cell Therapy Center, Shiga University of Medical Science, Otsu, Japan.
Am J Clin Pathol
September 2024
Department of Laboratory Medicine and Pathology, Center for Regenerative Biotherapeutics, Mayo Clinic, Rochester, MN, US.
Prenat Diagn
December 2024
Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Fetal Center, Houston, Texas, USA.
Objective: Congenital viral infection may result in fetal anemia and thrombocytopenia. While intrauterine blood transfusions (IUTs) are more commonly performed for Rh alloimmunization, reports using IUT for infection have varying success. Our primary objective was to characterize the outcomes of patients undergoing IUT for infectious etiologies at our center compared with Rh disease.
View Article and Find Full Text PDFHematol Transfus Cell Ther
November 2024
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Background And Objectives: The identification of platelet antibodies is essential for diagnosing and managing conditions such as fetal and neonatal alloimmune thrombocytopenic purpura, post-transfusion purpura, and immune platelet refractoriness. Monoclonal antibody immobilization of platelet antigens (MAIPA) is the standard method for detecting anti-human platelet antigen (HPA) antibodies, while the detection of anti-HLA antibodies once relied on the complement-dependent cytotoxicity method, however advanced technologies such as enzyme-linked immunosorbent assay and Luminex have significantly improved sensitivity and accuracy in identifying these antibodies. Flow cytometry-based techniques (platelet immunofluorescence test - PIFT) and Luminex platform-driven microsphere-based multiplex assays (Pak-Lx) are widely employed in platelet immunology laboratories owing to their remarkable flexibility and versatility.
View Article and Find Full Text PDFTransfus Med
December 2024
Transfusion Medicine Unit, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Introduction: Patients with hematologic malignancy have a higher risk of developing red blood cell (RBC) alloimmunization which can delay blood transfusion. Information on the risk factors for alloimmunization in this group is still limited. This study aimed to determine the prevalence and predictors of RBC alloimmunization among these patients.
View Article and Find Full Text PDFHematol Transfus Cell Ther
November 2024
Instituto de Ciências Biomédicas (ICBIM), Universidade Federal de Uberlândia (UFU), Uberlândia, MG, Brazil. Electronic address:
Indian J Pediatr
November 2024
Department of Clinical Hematology and Medical Oncology, PGIMER, Chandigarh, India.
Br J Haematol
October 2024
Department of Immunohaematology Diagnostic Services, Sanquin Diagnostic Services, Amsterdam, The Netherlands.
Hematol Transfus Cell Ther
November 2024
Departamento de Ciências Básicas da Saúde, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil. Electronic address:
J Trauma Acute Care Surg
September 2024
From the Division of Trauma and Acute Care Surgery, Department of Surgery (S.G., J.D., C.U., S.P., A.S., K.M., M.S., K.I., M.J.M.), Los Angeles General Medical Center, Los Angeles, California; Division of Trauma and Acute Care Surgery, Department of Surgery (J.D.), Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Trauma & Critical Care Surgery, Department of Surgery (J.P.H.), WellSpan York, York; Division of Trauma and Acute Care Surgery, Department of Surgery (J.O.), Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania; and Department of Surgery (J.G.), Joint Trauma System, San Antonio, Texas.
Background: Resuscitation with cold-stored whole blood (WB) has outcome benefits, but benefits varied by patient sex is unknown. There are also concerns about alloimmunization risk for premenopausal females given WB, leading to some protocols excluding this cohort. We sought to analyze WB utilization, outcomes, and disparities by patient sex.
View Article and Find Full Text PDFLancet Haematol
November 2024
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; Department of Clinical Pathology, University Health Network, Toronto, ON, Canada.
Anti-KEL1 antigen (also referred to as anti-Kell, or anti-K) alloimmunisation is the second most common cause of severe haemolytic disease of the fetus and newborn, after anti-rhesus D antigen, and can cause substantial fetal morbidity and mortality. Both fetal erythropoietic suppression and haemolysis contribute to anaemia. Typically, once a clinically significant alloantibody is identified during pregnancy, antibody titration is performed as a screening test to predict the risk of anaemia and the need for maternal-fetal medicine referral.
View Article and Find Full Text PDFJ Clin Med
August 2024
Department of Neonatology and Neonatal Intensive Care, Institute of Mother and Child, Kasprzaka 17a, 01-211 Warsaw, Poland.
Hemolytic disease of the fetus and newborn (HDFN) is caused by maternal antibodies attacking fetal blood cell antigens. Despite routine antenatal anti-D prophylaxis, intrauterine transfusions (IUTs) are still needed in some HDFN cases. We conducted a retrospective cohort study on newborns with HDFN born in the 1st Department of Obstetrics and Gynecology of the Medical University of Warsaw.
View Article and Find Full Text PDFAm J Perinatol
September 2024
Dell Medical School, The University of Texas at Austin, Austin, Texas.
Objective: Nipocalimab is a neonatal fragment crystallizable (Fc) receptor (FcRn)-blocking monoclonal antibody that inhibits placental immunoglobulin G (IgG) transfer and lowers circulating maternal IgG levels. In an open-label, single-arm, phase 2 study, nipocalimab demonstrated evidence of safety and efficacy that support further investigation in a pivotal phase 3 trial of recurrent hemolytic disease of the fetus and newborn (HDFN). The phase 3 AZALEA study aims to evaluate the efficacy and safety of nipocalimab in a larger population at risk for severe HDFN, defined as HDFN associated with poor fetal outcomes or neonatal death.
View Article and Find Full Text PDFSemin Thromb Hemost
August 2024
Department of Pediatrics, Unit of Pediatric Hematology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Bernard-Soulier syndrome (BSS) is an inherited platelet function disorder caused by mutations in the genes that encode the glycoprotein (GP) Ibα and GPIbβ subunits, as well as the GPIX subunit in the GPIbIX complex, which is located on the platelet surface and has roles in platelet adhesion and activation. Patients with autosomal recessively inherited biallelic BSS have a homozygous or compound heterozygous expression in the GPIbα, GPIbβ, and GPIX subunits of the GPIbIX complex. Patients with autosomal dominantly inherited monoallelic BSS have a heterozygous expression in only the GPIbα and GPIbβ subunits of the GPIbIX complex.
View Article and Find Full Text PDFSemin Thromb Hemost
August 2024
Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada.
Hematol Rep
August 2024
Programa de Pós-Graduação em Ciências Aplicadas à Hematologia da Universidade do Estado do Amazonas (PPGH-UEA), Manaus 69050-001, AM, Brazil.
Background: Sickle cell disease (SCD) affects approximately 100,000 people in the United States and millions worldwide, with the highest prevalence of 70% of SCD being found in individuals of African ethnicity. Delayed hemolytic, alloimmunization, and anamnestic transfusion reactions in multiple transfusion patients need to be investigated and managed to avoid a worsening of the patient's clinical status.
Objective: This paper aims to investigate delayed transfusion reactions in SCD patients who were polytransfused in the Brazilian Amazon.
Curr Opin Hematol
November 2024
Division of Hematology, Department of Medicine.
Purpose Of Review: Pregnancy for people with sickle cell disease (SCD) is high risk with persistently high rates of severe maternal and fetal mortality and morbidity. Transfusion therapy is the best-studied treatment for SCD in pregnancy; hydroxyurea is not usually used because of teratogenicity concerns. In high-resource settings, red cell transfusions are likely underutilized, while in low-resource settings, they may be altogether unavailable.
View Article and Find Full Text PDFThromb Haemost
September 2024
Division Clinical Research, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany.
Transfus Clin Biol
November 2024
Department of Transfusion Medicine, All India Institute of Medical Sciences, Patna, India.
Background And Objectives: With increasing life expectancy and prevalence of thalassaemia, it has led to a greater need for safe blood, yet the current supply from voluntary donors is insufficient to meet this demand. Thalassaemia recipients face a significant risk of alloimmunization because of repeated exposure to foreign red cell antigens. Study aims to determine high prevalent Rh antigen negative donors in western India donor population along with what percentage of these donors are willing to become dedicated voluntary donors for thalassaemia patients.
View Article and Find Full Text PDFObstet Gynecol
October 2024
Department of Women's Health, Dell Medical School, UT Health Austin, and the Comprehensive Fetal Center, Dell Children's Medical Center, Austin, Texas; and the Department of Obstetrics and Gynecology, Bridgeport Hospital/Yale University, Bridgeport, Connecticut.
Rhesus immune globulin has resulted in a marked decrease in the prevalence of RhD alloimmunization in pregnancy; however, antibody formation to other red cell antigens continues to occur. Evaluation for the presence of anti-red cell antibodies should be routinely undertaken at the first prenatal visit. If anti-red cell antibodies are detected, consideration of a consultation or referral to a maternal-fetal medicine specialist with experience in the monitoring and treatment of these patients is warranted.
View Article and Find Full Text PDFCureus
July 2024
Transfusion Medicine, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, IND.
Anti-Lewis antibodies are often not clinically significant since they do not react at 37°C. These antibodies have, however, occasionally been linked to hemolytic transfusion reactions (HTR). We report a case of naturally occurring anti-Lewis-a (Le-a) in a 58-year-old patient found during routine blood grouping.
View Article and Find Full Text PDFTransfus Med Rev
October 2024
Standards Development and Quality Initiatives, Association for the Advancement of Blood and Biotherapies, Bethesda, MD, USA.
The actual risk of providing RhD-positive units to RhD-negative recipients remains debatable. There is no standard of care in the United States (US) to guide transfusion decisions regarding RhD type for patients with an unknown blood type, except for women of childbearing age and neonates. The risk of alloantibody formation by an RhD-negative patient exposed to RhD-positive blood is reported to be from 3% to 70%.
View Article and Find Full Text PDFFront Pain Res (Lausanne)
July 2024
Department of Woman, Mother and Neonate, Buzzi Children's Hospital, University of Milan, Milan, Italy.
Introduction: Intrauterine transfusion is the treatment for fetal anemia resulting from maternal alloimmunization, infections (parvovirus B19 and cytomegalovirus), single demise of a monochorionic twin, chorioangioma, and other rare conditions. Fetal analgesia is mandatory to reduce movement and pain perception during the procedure. This study aims to evaluate perinatal outcomes for such procedures, following the routine use of fetal analgesia in our clinical practice.
View Article and Find Full Text PDFLab Med
August 2024
Immunogenetics, Cell Therapy and Blood Transfusion Research Laboratory (LR20SP05), Department of Immunohaematology, National Blood Transfusion Centre of Tunis, University of Tunis El Manar, Tunis, Tunisia.
Background: The presence of some red blood cell (RBC) antigens may affect the preference for using type O blood in emergency situations because they may induce complex or multiple alloimmunization in special circumstances.
Methods: A subgroup of 77 type O blood Tunisian donors were genotyped for 19 common blood alleles using the single specific primer-polymerase chain reaction method. The statistical analysis was done using HaploView software.